Zevid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zevid

Property Description
Active ingredient Ofloxacin
Form Tablet, Solution for infusion, Ophthalmic/Otic solution
Pharmacological class Fluoroquinolone Antibiotic
General purpose Elimination of susceptible bacterial infections
Origin Synthetic
Regulatory Status Prescription-only medicine (Rx)

Zevid: Identity, Classification, and Composition

Zevid is a prescription medication that contains the active substance Ofloxacin as a single component. This compound is classified as a synthetic fluoroquinolone antibiotic, a specific and potent class of antimicrobial agents used to address bacterial infections. The drug is manufactured by companies such as Zee Laboratories and Swiss Pharma and is strictly available as a prescription-only medicine, underscoring its intended use under professional guidance.


Available Forms and Bactericidal Action

Ofloxacin is recognized for its broad-spectrum capabilities against a variety of bacteria. The medication is available in multiple dosage forms, including the standard tablet for oral administration and the solution for infusion for systemic intravenous use. Specialized ophthalmic (eye) and otic (ear) solutions are also manufactured for topical delivery to treat localized surface infections.


The general purpose of Zevid is to act as a definitive bactericidal agent. This means its primary objective is to eliminate bacterial infections by actively killing the microorganisms. The drug works by disrupting the bacteria's genetic material (DNA), effectively preventing the necessary cellular processes for replication and survival. This action aids in the swift clearance of established infections.

Regulatory References

  1. Ofloxacin: MedlinePlus Drug Information

What side effects are possible with Zevid?

Possible Side Effects and Safety Information

The safety profile of Zevid, as documented in official government regulatory labeling, establishes a factual framework of potential risks.

Documented Adverse Reactions

Adverse reactions are formally categorized by their frequency of occurrence and the major body system affected (System-Organ Class or SOC):

Classification Scope Examples of Documented Events
Common Side Effects Nausea, vomiting, diarrhea, metallic taste, headache, and dizziness are frequently documented adverse events.
System-Organ Classes Events are documented across categories including Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, and Psychiatric Disorders.
Serious Adverse Reactions Infrequent but clinically significant reactions listed in regulatory documents include Tendon Rupture, severe Hypersensitivity/Anaphylactic Reactions, and serious Liver Dysfunction.

Safety Constraints and Considerations

The official labeling details specific limitations and warnings related to the use of Zevid:

  • Population Restrictions: Explicit safety statements are provided for specific patient groups, including pregnant women and individuals with Hepatic or Renal Impairment. These statements define mandatory caution or avoidance based on the regulatory assessment.
  • Duration/Exposure Patterns: The risk of certain serious effects, such as tendon-related issues, may be linked to the duration of treatment, as noted in regulatory texts.
  • Mandatory Restrictions: The label restricts use in patients with a history of tendon disorders associated with similar antibiotics and requires caution regarding activities like driving due to the potential for dizziness. Use with alcohol is explicitly restricted due to the risk of a severe reaction.

Overdose and Emergency Response

Zevid (Ofloxacin) overdose is documented in regulatory sources as potentially affecting the Central Nervous System (CNS) and Cardiovascular System. Officially reported manifestations of overexposure include severe CNS disturbances such as convulsions, toxic psychosis, and tremors, alongside symptoms like acute confusion and nausea. Overexposure also carries a risk of life-threatening outcomes, including the precipitation of seizures and severe cardiac risks. Specifically, official warnings note QT interval prolongation, which is associated with the dangerous arrhythmia Torsades de pointes.

Required Emergency Actions

Immediate medical attention is required for severe manifestations. Regulatory documents mandate that patients seek immediate medical attention for symptoms such as seizures, confusion, or loss of consciousness, and that the drug be discontinued immediately upon the first signs of serious adverse reactions. Management is focused on non-specific symptomatic and supportive treatment, as no specific antidote is known. Procedures may include continuous observation with ECG monitoring to detect cardiac changes and monitoring of serum concentrations. Due to the drug's elimination route, elderly patients and those with impaired renal function are identified as having an increased risk of enhanced toxicity from high systemic exposure.

Therapeutic Uses of Zevid

What Zevid Treats: Main Uses and Benefits

Zevid is considered relevant as part of symptomatic management of symptoms that create noticeable physiological strain or discomfort, commonly used when short-term symptomatic assistance is needed. The use of supportive, short-term management is an established approach for managing acute manifestations.


Easing Acute Symptomatic Discomfort

Zevid is commonly used when symptoms related to physical discomfort or heightened physiological activity intensify, and supportive relief is appropriate. It contributes to easing the overall symptom load, particularly during phases of increased distress or discomfort. This medicine may be part of symptomatic management for conditions presenting with acute episodes and those characterized by periods of heightened symptoms.

Management and Support

This medicine is considered relevant across conditions involving episodic or fluctuating manifestations, often applied in clinical settings that involve acute or disruptive symptom patterns. It plays a role in managing symptom clusters that may become intense or disruptive, assisting with maintaining functional stability and comfort during symptomatic phases. Zevid is relevant in contexts involving symptoms that interfere with daily functioning or escalate temporarily.


Symptomatic Support Overview
Zevid is commonly used to help with symptoms associated with acute or episodic changes, and may assist with supportive relief when management of discomfort is required.

Regulatory References

  1. NIH StatPearls on Pain Management Medications

Eligibility and Restrictions for Use

Zevid (Ofloxacin) eligibility is strictly defined by regulatory authorities and is primarily restricted to adults.

Absolute Contraindications

The medicine is contraindicated and must not be used in the following populations:

  • Patients with a known hypersensitivity to Ofloxacin or any fluoroquinolone antibiotic.
  • Patients with a history of tendon disorders related to previous fluoroquinolone use.
  • Individuals with a history of epilepsy, an existing CNS disorder with a lowered seizure threshold, or myasthenia gravis.
  • Children or growing adolescents and pregnant or breastfeeding women (as specified in some regulatory labeling).

Conditional Use and Restrictions

Use of Zevid is permitted only under restrictive conditions for specific populations and comorbidities:

  • Patients with impaired renal function require mandatory dosage adjustment.
  • Patients with severe hepatic dysfunction require dosage limitation.
  • Special caution is necessary for older adults, solid organ transplant recipients, and patients taking corticosteroids due to a heightened risk of tendon rupture.
  • Additional caution is required for patients with known risk factors for QT prolongation or other severe cardiac arrhythmias.

What should I know about interactions with other medicines?

The official regulatory profile for Zevid (Ofloxacin) structures its interaction information around agents that significantly alter its exposure and those that pose risks due to additive pharmacodynamic effects.

Key Interaction Classes and Regulatory Constraints

  • Absorption Interference: Substances containing metal cations (e.g., Antacids, Iron, Zinc, Sucralfate) interfere with Zevid’s absorption through chelation, which reduces its serum concentration. Regulatory labeling mandates that these agents must not be taken within two hours before or two hours after Zevid administration.
  • Pharmacodynamic Risks: Use with medicines known to prolong the QT interval (e.g., certain antiarrhythmics) should be approached with caution due to the risk of cardiac conduction disturbances. The co-administration of agents that lower the cerebral seizure threshold, such as Theophylline or certain NSAIDs, may lead to an increased risk of CNS effects.
  • Monitoring Requirements: Zevid may enhance the effects of Vitamin K Antagonists (e.g., Warfarin), requiring clinical monitoring of coagulation status. Concomitant use with Antidiabetic Agents (e.g., Glibenclamide) requires monitoring due to the risk of blood glucose disturbances.
  • Clearance and Exposure: The kidney tubular secretion inhibitor Probenecid reduces Zevid's clearance, resulting in increased systemic exposure of the antibiotic. This exposure is also naturally reduced in patients with impaired renal function and elderly subjects.

Mechanism of Action

Inhibiting Bacterial DNA Gyrase and Topoisomerase IV

Zevid (Ofloxacin) operates through the specific inhibition of two critical bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. By binding to the transient complex formed between these enzymes and the bacterial DNA, Ofloxacin stabilizes it, which prevents the enzymes from executing their roles of unwinding and separation of the DNA strands. This interference affects the pathways governing bacterial structure and replication.

Inducing Catastrophic Genetic Damage (Bactericidal Cascade)

This molecular action triggers a mechanistic cascade resulting in active cell death. The functional blockage of the enzymes leads to an accumulation of DNA double-strand breaks and torsional stress, which the microorganism cannot repair. This disruption of genetic integrity results in the induction of bactericidal cell death in susceptible microbial populations, a physiological change consistent with the drug's mechanism of action.

️ Constraints and Mechanism Limitations

The mechanism's action is based on selective toxicity but is also subject to constraints. Its effectiveness can be limited by microbial characteristics such as intrinsic resistance in some obligate anaerobes. Furthermore, the action is functionally overcome by acquired bacterial resistance mechanisms, including mutations in the target enzyme genes (gyrA, parC) and the expression of efflux pumps that actively prevent the molecule from reaching its intracellular target site.

Dosage and Administration Information

Zevid (Ofloxacin) is prescribed for administration across several official routes. Systemic delivery is achieved using oral tablets or intravenous (IV) infusion, while localized treatment employs topical ophthalmic (eye) and otic (ear) solutions.

Standard Administration Protocol

Standard adult systemic dosing typically involves a total daily amount ranging from 400 mg to 800 mg, administered in unit doses of 200 mg, 300 mg, or 400 mg. Systemic treatment is generally scheduled twice daily, maintaining a 12-hour interval. A specific approved regimen includes a single 400 mg dose for certain uncomplicated infections. The treatment duration is strictly defined for the medication, ranging from a short, single-day course up to a six-week course for specific chronic infections.

Contextual and Special Requirements

The oral tablets may be taken with or without food. A key procedural constraint is that the oral formulation must be administered at least two hours before or after products containing multivalent cations, such as antacids, to ensure proper absorption. The intravenous solution must be administered via slow infusion over 60 minutes. The ophthalmic solution is specifically restricted from administration via injection.

Dosage adjustment is formally mandated for patients demonstrating renal impairment, specifically when creatinine clearance is <50 mL/min. This modification to the dose or interval applies to all adults whose kidney function is reduced. If a systemic dose is missed, standard instructions involve taking it when remembered, but not to double the subsequent dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zevid


Evidence for Systemic Infections: Urinary Tract and Respiratory Uses

The research landscape for Zevid (Ofloxacin) primarily relies on Randomized Controlled Trials (RCTs) and comparative studies, which was studied for conditions associated with acute or disruptive episodes, such as complicated and uncomplicated urinary tract infections (UTIs). These trials research examined measurements of the rate of bacterial clearance (bacteriological eradication rate) and studies monitored changes in physical discomfort and other related symptoms. Trials data show patterns related to changes in infection symptoms over defined time intervals when Ofloxacin was utilized versus alternative treatments. The evidence quality varies across studies, and comparative evidence against newer, non-fluoroquinolone antibiotics is generally lacking.

For lower respiratory tract infections, such as pneumonia and acute exacerbations of chronic bronchitis, trials was evaluated in settings focusing on outcomes linked to inflammatory or irritative states. Researchers primarily assessed the clinical success/failure rates and the clearance of bacteria from the lungs. Studies report how symptoms evolved in the observed populations of adults with these conditions. Many primary studies are older, which may not fully reflect its activity against the evolving profile of current respiratory pathogens.


Evidence for Deep-Seated and Localized Infections

The drug was studied for chronic bacterial prostatitis in adult men. This research involved comparative clinical trials that required extended treatment courses to evaluate the measured outcomes. These studies research explored the microbiological clearance from the prostate gland. Evidence is limited for this indication compared to UTIs, and some research was conducted using studies of closely related agents within the same pharmacological class. Zevid was observed in trials for pelvic inflammatory disease (PID) in adult women, where it was evaluated in settings that involved combination therapy in some studies.


Evidence for Topical Use: Eye and Ear Solutions

The research base for the topical use of Zevid (as eye drops and ear drops) includes systematic reviews and dedicated Phase III Clinical Trials. The otic (ear) solution was studied for external and middle ear infections. These studies research examined measurements of ear drainage (otorrhea) and bacteriological eradication. The ophthalmic (eye) solution was studied for superficial eye infections such as bacterial conjunctivitis. Data for certain groups remain insufficient, particularly infants younger than six months for otitis externa.


Key Evidence Gaps and Areas of Uncertainty

A consistent pattern across the regulatory evidence is that follow-up durations were limited. Most key clinical trials studies observed responses over defined time intervals coinciding with or immediately following the short course of antibiotic therapy. Therefore, there is limited information for long-term outcomes regarding the sustained absence of infection or the durability of the microbiological clearance over months or years. The scientific literature highlights several areas where certainty remains low or research is still needed. Ongoing scientific monitoring research monitors the factor of emerging bacterial resistance to fluoroquinolones, which is a factor that can affect the drug's activity in real-world settings.

Frequently Asked Questions (FAQ)

Common questions about Zevid (FAQ)


Q: Why does Zevid have a specific warning about a certain population group?

A: Official regulatory labeling indicates that specific warnings for certain populations, such as older adults or those taking corticosteroids, are necessary. This is due to an increased risk of serious adverse reactions, such as tendon rupture, being observed in these groups.


Q: Can Zevid be taken by elderly patients?

A: Official documents on the drug's action in the body (pharmacology) note that the elimination of Zevid can be slower in older adults. This slower rate may lead to higher concentrations of the medicine in the blood. Therefore, if an elderly patient has reduced kidney function, dosage adjustments may be necessary according to prescribing information.


Q: How long does it usually take to notice the effects of Zevid?

A: The official pharmacological data indicates how quickly the medicine enters the system. It shows that the maximum concentration of the drug in the blood is generally reached one to two hours after taking an oral dose. This is the time it typically takes for the active ingredient to reach its highest level in the bloodstream.


Q: Is it normal to feel a bit tired when starting Zevid?

A: Official safety documents list certain nervous system side effects that may occur, including headache and dizziness. Unusual tiredness or weakness has also been observed in some cases, along with sleep problems. These effects are documented in official reports of adverse events.


Q: What are the most common reasons a doctor would prescribe Zevid?

A: According to the official regulatory indications, Zevid is used to treat specific susceptible bacterial infections. These officially approved uses include certain types of urinary tract infections (UTIs), pneumonia, skin and skin structure infections, and prostatitis.


Q: How is Zevid generally supposed to be stopped or discontinued?

A: Patient information guides indicate that the medicine is prescribed for a full, specific length of time. Regulatory guidance states that the medicine is intended to be used for the entire prescribed duration and is not to be stopped without consultation with the prescribing healthcare provider.


Q: Why do some patient communities refer to Zevid as a 'second-line' treatment?

A: Official labeling places limitations on the use of this class of antibiotics for certain infections, such as uncomplicated UTI. For these specific conditions, the drug is reserved for patients who are described as having no other available treatment options.


Q: What should I do if a side effect from Zevid seems mild but bothersome?

A: Official patient medication guides advise that patients consult their healthcare provider if they experience any side effects that bother them or do not go away. Patients are also advised of a process to report observed side effects to national health agencies.


Q: Does Zevid have any known effects on sleep patterns?

A: Yes, official safety documents list sleep problems as a documented adverse effect. This effect, which may include trouble sleeping or insomnia, is reported in the official adverse reactions sections.


Q: Is Zevid available as a generic medicine?

A: Official drug registries and listings confirm that the active ingredient, Ofloxacin, is manufactured by various companies. This information is consistent with the drug being available in generic formulations under different brand names.


Q: What does the research say about Zevid's effectiveness in different age groups?

A: Studies for topical formulations (eye or ear drops) often include specific findings on safety and dosing for children above a certain age (e.g., six months). For systemic use, efficacy is primarily observed in adults, though pharmacokinetic differences are noted for the elderly.


Q: What are the signs of a serious allergic reaction to Zevid?

A: Official warnings state that serious allergic reactions (anaphylaxis) may present with signs such as swelling (e.g., face or throat), difficulty breathing or airway obstruction, or loss of consciousness. Other signs may include hives, itching, or a severe rash.


Q: Can Zevid be crushed, split, or chewed?

A: Official patient instructions emphasize that the medication is to be used exactly as prescribed. Furthermore, documentation related to disposal procedures states that the tablets are not to be crushed, which implies a procedural constraint against altering the physical form of the tablet.


Q: Does Zevid interact with birth control pills?

A: Official sources note that there is generally not a significant interaction classified between this class of antibiotics and combined hormonal contraceptives. However, some patient materials suggest consulting a healthcare provider about possible theoretical risks or the need for a back-up method.


Q: What is the official definition of a 'contraindication' for Zevid?

A: In authoritative medical sources, the term contraindication is defined as a specific situation or condition where a medicine should not be used. This is because using the drug in that situation presents a risk to the person.


Q: What happens if Zevid is taken at a higher-than-usual dose or accidentally doubled?

A: Official patient information indicates that if an overdose is suspected, or if a higher dose than usual is taken, emergency medical attention is required immediately. This advice includes calling a poison help line right away.


Q: What are the officially listed inactive ingredients in Zevid?

A: Official drug listings detail the full composition of the medication. This includes the active ingredient (Ofloxacin) and various inactive ingredients, such as specific fillers, binders, and coloring agents, which can vary depending on the dosage form and the manufacturer.


Q: How does Zevid's mechanism of action relate to its side effect profile?

A: Official warnings explicitly link the drug class (fluoroquinolones) to disabling adverse effects, such as tendon damage, nerve damage (peripheral neuropathy), and central nervous system effects. These effects are understood to be related to the drug's core molecular mechanism that targets related enzymes.

How should Zevid be stored and disposed of?

The storage and disposal of Zevid (ofloxacin) must follow the specific requirements outlined in official regulatory labeling.

Official Storage and Handling

Requirement Details
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), allowing brief excursions up to 30 C (86 F).
Protection Keep the medicine from freezing and protect it from excessive heat, moisture, and light.
Container The container must be kept tightly closed. Ophthalmic and otic solution tips must remain sterile.
Safety Keep the product out of the reach of children.
Expiration Do not keep or use outdated medicine past its expiration date.

Disposal Instructions

Unused or expired Zevid should preferably be disposed of through a drug take-back program or mail-back envelope. If these options are unavailable, the medicine must be removed from its original container, mixed with an undesirable substance like dirt or cat litter, and sealed in a plastic bag before being placed in the household trash. Tablets must not be crushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zevid found in:

A-Z Index: